Arylvinylpiperazine amides, a new class of potent inhibitors targeting QcrB of Mycobacterium tuberculosis

• Main Authors: Foo, Caroline S., Lupien, Andréanne, Kienle, Maryline, Vocat, Anthony, Benjak, Andrej, Sommer, Raphael, Lamprecht, Dirk A., Steyn, Adrie J. C., Pethe, Kevin, Piton, Jérémie, Altmann, Karl-Heinz, Cole, Stewart T.
• Other Authors: Nacy, Carol A.
• Format: Article
• Language: English
• Published: 2019
• Subjects: Cytochrome Bc1 Oxidase; QcrB Inhibitor; Science::Medicine
• Online Access: https://hdl.handle.net/10356/87647; http://hdl.handle.net/10220/49884
• Institution: Nanyang Technological University

New drugs are needed to control the current tuberculosis (TB) pandemic caused by infection with Mycobacterium tuberculosis. We report here on our work with AX-35, an arylvinylpiperazine amide, and four related analogs, which are potent antitubercular agents in vitro. All five compounds showed good a...